| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
PT Phapros Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp350.00 |
| 52 Week High | Rp1,000.00 |
| 52 Week Low | Rp302.00 |
| Beta | 0.30 |
| 11 Month Change | 7.36% |
| 3 Month Change | -29.44% |
| 1 Year Change | -48.91% |
| 33 Year Change | -69.96% |
| 5 Year Change | -80.17% |
| Change since IPO | -80.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| PEHA | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | -0.6% | 0.4% | -1.2% |
| 1Y | -48.9% | -18.1% | 9.4% |
Return vs Industry: PEHA underperformed the ID Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: PEHA underperformed the ID Market which returned 9.4% over the past year.
Price Volatility
| PEHA volatility | |
|---|---|
| PEHA Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in ID Market | 12.8% |
| 10% least volatile stocks in ID Market | 2.9% |
Stable Share Price: PEHA's share price has been volatile over the past 3 months.
Volatility Over Time: PEHA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 1,453 | Ida Kurniasih | www.phapros.co.id |
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Ethical; Generic Drugs Bearing; and Toll-in Manufacturing segments. It offers OTC drugs, including Antimo Anak, Livron B Plek, Noza, Hemorogard, Bioron, and others through pharmacies, retail, and drug stores.
PT Phapros Tbk Fundamentals Summary
| PEHA fundamental statistics | |
|---|---|
| Market cap | Rp294.00b |
| Earnings (TTM) | -Rp28.19b |
| Revenue (TTM) | Rp924.20b |
0.3x
P/S Ratio-10.4x
P/E RatioIs PEHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEHA income statement (TTM) | |
|---|---|
| Revenue | Rp924.20b |
| Cost of Revenue | Rp485.28b |
| Gross Profit | Rp438.92b |
| Other Expenses | Rp467.11b |
| Earnings | -Rp28.19b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -33.56 |
| Gross Margin | 47.49% |
| Net Profit Margin | -3.05% |
| Debt/Equity Ratio | 99.6% |
How did PEHA perform over the long term?
See historical performance and comparison